New Health Sciences, Inc.

Lexington, MA Doing business as Hemanext Inc.

UEI
CC3QRDB7EYX7
CAGE
47HT2
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
99 Hayden Ave Ste 620 Bldg B, Lexington, MA 02421, USA
Website
hemanext.com
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Grant awards

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
Duke University Dr. Yoshida and the Hemanext team will both prepare hypoxically stored, deidentified human RBC units and will also train the Duke team in their preparation.… R01HL161071 $69,334

Similar vendors

About the company

New Health Sciences, Inc., doing business as Hemanext Inc., is a for-profit corporate entity registered in the System for Award Management (SAM) since November 2005, with a focus on developing innovative medical technologies related to blood cell processing and storage. Based in Lexington, Massachusetts, the company specializes in manufacturing medical technologies and research systems designed to improve blood transfusion techniques, particularly for patients with complex blood disorders. The company's core competency appears to be developing advanced systems for processing and storing red blood cells and whole blood under optimized conditions that potentially enhance their medical utility.

The company has been awarded multiple federal grants from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program, focusing on innovative blood transfusion technologies. Their recent grants include a $1,017,232 project to assess hypoxic red blood cell (HRBC) transfusions for sickle cell anemia patients and a $295,963 grant to evaluate platelet function under hypoxic storage conditions for whole blood transfusion. Additionally, Hemanext has engaged in collaborative research through sub-awards, such as a partnership with Duke University, where they prepare hypoxically stored, deidentified human red blood cell units and provide technical expertise on research investigating the effects of hypoxic storage on red blood cell characteristics. Their research aims to develop more advanced blood storage platforms that maintain cell viability, reduce oxidative damage, and potentially improve transfusion outcomes for patients with complex medical conditions.

Quick answers

Is New Health Sciences, Inc. registered in SAM.gov?

Yes. New Health Sciences, Inc.'s SAM.gov registration is active through June 5, 2027.

What is New Health Sciences, Inc.'s CAGE code?

New Health Sciences, Inc.'s CAGE code is 47HT2, and its Unique Entity ID (UEI) is CC3QRDB7EYX7.

What is New Health Sciences, Inc.'s most recent federal award?

New Health Sciences, Inc.'s most recent federal grant award is Efficacy of hypoxic red blood cells processed with the hemanext one® system in patients with sickle cell anemia (R44HL178006), from National Heart Lung and Blood Institute (NIH), on September 5, 2025.

On GovTribe

See New Health Sciences, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe